Adicet Bio, Inc. — Investor Relations & Filings

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies. The company's core mission is to create 'off-the-shelf' treatments for patients with cancer and autoimmune diseases. By engineering gamma delta T cells, Adicet aims to provide readily available and potent immunotherapies. Its proprietary platform is designed to leverage the unique characteristics of these cells, which possess both innate and adaptive immune properties, to develop potentially first-in-class and best-in-class therapeutic candidates that can effectively target and eliminate diseased cells.